Clinical Trials Browser

Phase 2 × Thyroid Neoplasms × sintilimab × Clear all

NCT06787911 2025-01-22

Donafenib Combined With Anti-PD-1 Antibody for Neoadjuvant Therapy in Locally Advanced Thyroid Cancer

Phase 2 Recruiting

Thyroid Neoplasms